XW0Level 3

New Technology, Anatomical Regions, Introduction

Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products

GET/api/v1/systems/icd10_pcs/nodes/XW0

Official DownloadPublic Domain (US Government)Source

Hierarchy Explorer

Hierarchy ExplorerChevron to expand - click title to open

XW00X27Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7

XW01318Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8

XW01329Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9

XW01348Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8

XW0136AIntroduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10

XW01397Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7

XW013F5Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5

XW013G6Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

XW013H6Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

XW013K6Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

XW013L9Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9

XW013S6Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

XW013S9Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9

XW013T6Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

XW013U6Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

XW013V7Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7

XW013W5Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5

XW013W7Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7

XW01X27Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7

XW020D8Introduction of Engineered Allogeneic Thymus Tissue into Muscle, Open Approach, New Technology Group 8

XW023S6Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6

XW023T6Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6

XW023U6Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6

XW023V7Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7

XW023W7Introduction of COVID-19 Vaccine Booster into Muscle, Percutaneous Approach, New Technology Group 7

XW023X7Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7

XW023Y7Introduction of Other New Technology Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7

XW03306Introduction of Brexanolone into Peripheral Vein, Percutaneous Approach, New Technology Group 6

XW03308Introduction of Spesolimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 8

XW03326Introduction of Nerinitide into Peripheral Vein, Percutaneous Approach, New Technology Group 6

XW03336Introduction of Durvalumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6

XW0333AIntroduction of Bentracimab, Ticagrelor Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 10

XW0334AIntroduction of Cefepime-taniborbactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10

XW03357Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7

XW03358Introduction of Mosunetuzumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 8

XW0335AIntroduction of Ceftobiprole Medocaril Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10

XW03366Introduction of Lefamulin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6

XW03367Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7

XW03368Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8

XW03372Introduction of Inactivated Coagulation Factor Xa into Peripheral Vein, Percutaneous Approach, New Technology Group 2

XW03377Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7

XW03378Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8

XW03387Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7

XW03388Introduction of Treosulfan into Peripheral Vein, Percutaneous Approach, New Technology Group 8

XW0338AIntroduction of Obecabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 10

XW03396Introduction of Ceftolozane/Tazobactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6

XW03398Introduction of Inebilizumab-cdon into Peripheral Vein, Percutaneous Approach, New Technology Group 8

XW0339AIntroduction of Odronextamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10

XW033A6Introduction of Cefiderocol Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6

XW033A7Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7

XW033B3Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3

XW033B6Introduction of Omadacycline Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6

XW033B7Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7

XW033BAIntroduction of Orca-T Allogeneic T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10

XW033C6Introduction of Eculizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 6

XW033C7Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

XW033CAIntroduction of Zanidatamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10

XW033D6Introduction of Atezolizumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6

XW033DAIntroduction of Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension into Peripheral Vein, Percutaneous Approach, New Technology Group 10

XW033E5Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5

XW033E6Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6

XW033F3Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 3

XW033F5Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5

XW033F6Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6

XW033FAIntroduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10

XW033G5Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5

XW033G6Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6

XW033G7Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

XW033H5Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5

XW033H6Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6

XW033H7Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

XW033J7Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

XW033K7Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

XW033K9Introduction of Sulbactam-Durlobactam into Peripheral Vein, Percutaneous Approach, New Technology Group 9

XW033L6Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6

XW033L7Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

XW033M7Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

XW033N7Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7

XW033P9Introduction of Glofitamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 9

XW033Q5Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5

XW033Q9Introduction of Posoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 9

XW033R9Introduction of Rezafungin into Peripheral Vein, Percutaneous Approach, New Technology Group 9

XW033S5Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5

XW033W5Introduction of Caplacizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5

XW04306Introduction of Brexanolone into Central Vein, Percutaneous Approach, New Technology Group 6

XW04308Introduction of Spesolimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 8

XW04326Introduction of Nerinitide into Central Vein, Percutaneous Approach, New Technology Group 6

XW04336Introduction of Durvalumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6

XW0433AIntroduction of Bentracimab, Ticagrelor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 10

XW0434AIntroduction of Cefepime-taniborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10

XW04357Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7

XW04358Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8

XW0435AIntroduction of Ceftobiprole Medocaril Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10

XW04366Introduction of Lefamulin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6

XW04367Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7

XW04368Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8

XW04372Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2

XW04377Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7

XW04378Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8

XW04387Introduction of Lurbinectedin into Central Vein, Percutaneous Approach, New Technology Group 7

XW04388Introduction of Treosulfan into Central Vein, Percutaneous Approach, New Technology Group 8

XW0438AIntroduction of Obecabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 10

XW04396Introduction of Ceftolozane/Tazobactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6

XW04398Introduction of Inebilizumab-cdon into Central Vein, Percutaneous Approach, New Technology Group 8

XW0439AIntroduction of Odronextamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10

XW043A6Introduction of Cefiderocol Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6

XW043A7Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7

XW043B3Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3

XW043B6Introduction of Omadacycline Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6

XW043B7Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7

XW043BAIntroduction of Orca-T Allogeneic T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 10

XW043C6Introduction of Eculizumab into Central Vein, Percutaneous Approach, New Technology Group 6

XW043C7Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

XW043CAIntroduction of Zanidatamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10

XW043D6Introduction of Atezolizumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6

XW043E5Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5

XW043E6Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

XW043F3Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 3

XW043F5Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5

XW043F6Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

XW043FAIntroduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Central Vein, Percutaneous Approach, New Technology Group 10

XW043G5Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5

XW043G6Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

XW043G7Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

XW043H5Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5

XW043H6Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

XW043H7Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

XW043J7Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

XW043K7Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

XW043K9Introduction of Sulbactam-Durlobactam into Central Vein, Percutaneous Approach, New Technology Group 9

XW043L6Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6

XW043L7Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

XW043M7Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

XW043N7Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

XW043P9Introduction of Glofitamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 9

XW043Q5Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5

XW043Q9Introduction of Posoleucel into Central Vein, Percutaneous Approach, New Technology Group 9

XW043R9Introduction of Rezafungin into Central Vein, Percutaneous Approach, New Technology Group 9

XW043S5Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5

XW043W5Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5

XW053T9Introduction of Melphalan Hydrochloride Antineoplastic into Peripheral Artery, Percutaneous Approach, New Technology Group 9

XW0DX38Introduction of Maribavir Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 8

XW0DX66Introduction of Lefamulin Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 6

XW0DX82Introduction of Uridine Triacetate into Mouth and Pharynx, External Approach, New Technology Group 2

XW0DXF5Introduction of Other New Technology Therapeutic Substance into Mouth and Pharynx, External Approach, New Technology Group 5

XW0DXJ9Introduction of Quizartinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 9

XW0DXK8Introduction of Sabizabulin into Mouth and Pharynx, External Approach, New Technology Group 8

XW0DXM6Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6

XW0DXN9Introduction of SER-109 into Mouth and Pharynx, External Approach, New Technology Group 9

XW0DXR7Introduction of Fostamatinib into Mouth and Pharynx, External Approach, New Technology Group 7

XW0G738Introduction of Maribavir Anti-infective into Upper GI, Via Natural or Artificial Opening, New Technology Group 8

XW0G7K8Introduction of Sabizabulin into Upper GI, Via Natural or Artificial Opening, New Technology Group 8

XW0G7M6Introduction of Baricitinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 6

XW0G7R7Introduction of Fostamatinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 7

XW0G886Introduction of Mineral-based Topical Hemostatic Agent into Upper GI, Via Natural or Artificial Opening Endoscopic, New Technology Group 6

XW0H738Introduction of Maribavir Anti-infective into Lower GI, Via Natural or Artificial Opening, New Technology Group 8

XW0H7K8Introduction of Sabizabulin into Lower GI, Via Natural or Artificial Opening, New Technology Group 8

XW0H7M6Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6

XW0H7R7Introduction of Fostamatinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 7

XW0H7X8Introduction of Broad Consortium Microbiota-based Live Biotherapeutic Suspension into Lower GI, Via Natural or Artificial Opening, New Technology Group 8

XW0H886Introduction of Mineral-based Topical Hemostatic Agent into Lower GI, Via Natural or Artificial Opening Endoscopic, New Technology Group 6

XW0J3HAIntroduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10

XW0J3JAIntroduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10

XW0J3KAIntroduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10

XW0J3LAIntroduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10

XW0K3HAIntroduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10

XW0K3JAIntroduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10

XW0K3KAIntroduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10

XW0K3LAIntroduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10

XW0L3HAIntroduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10

XW0L3JAIntroduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10

XW0L3KAIntroduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10

XW0L3LAIntroduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10

XW0M3HAIntroduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10

XW0M3JAIntroduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10

XW0M3KAIntroduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10

XW0M3LAIntroduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10

XW0Q316Introduction of Eladocagene exuparvovec into Cranial Cavity and Brain, Percutaneous Approach, New Technology Group 6

XW0U0GAIntroduction of Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System into Joints, Open Approach, New Technology Group 10

XW0V0P7Introduction of Antibiotic-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7

XW0V3WAIntroduction of AGN1 Bone Void Filler into Bones, Percutaneous Approach, New Technology Group 10

Cross-system equivalences0

No cross-system equivalences mapped for this node.

Report a data issue